Method of treating dermatosis and detoxication agent for implementing it

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to dermatology, and describes a method of treating dermatosis based on patient's detoxication by binding toxins with using enterosorbents and discharge them. The method involves dissolving toxins and stimulating diuresis with using an infusion therapy, administering normal saline, administering a diuretic which is presented by lasix, stimulating the blood microcirculation, including at the level of small vessels with using Fraxiparine, low-molecular heparin, with the agent nadroparin calcium; the enterosorbent is Polysorb.

EFFECT: method enables increasing the clinical effectiveness for dermatosis by the smooth effect of the homeostasis system and detoxification, reducing the body intoxication, dehydration and hypercoagulation, improving the small microcirculation and can be used in treating severe forms of chronic dermatosis and psoriasis.

6 cl, 1 tbl, 1 dwg, 2 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula , which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.

EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.

47 cl, 1 tbl, 54 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel N-containing heteroaryl derivatives of formula I or II or their pharmaceutically acceptable salts, which possess properties of JAK kinase, in particular JAK3, and can be applied for treating such diseases as asthma and chronic obstructive pulmonary disease (COPD). In formulae A represents carbon and B represents nitrogen or A represents nitrogen and B represents carbon; W represents CH or N; R1 and R2, independently represent hydrogen, C1-4alkyl, halogenC1-4alkyl, -CN; R3 represents C1-4alkyl, R9-C1-4alkyl, Cy1, where Cy1 is optionally substituted with one or several substituents R10; R4 represents hydrogen, C1-4alkyl, R12R7N-C0alkyl, where one of R7 and R12 represents hydrogen, and the other represents C1-4alkyl or group R13, which is selected from C1-5alkyl, Cy2-C0alkyl; R5 represents hydrogen; R6 represents hydrogen, C1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl, R12R7N-C1-4alkyl, R16CO-C0alkyl, Cy1; R7 represents hydrogen or C1-4alkyl; R9 represents halogen, -CN, -CONR7R12, -COR13, CO2R12, -OR12, -SO2R13, -SO2NR7R12, -NR7R12, -NR7COR12; R10 represents C1-4alkyl or R9-C0-4alkyl; R11 represents C1-4alkyl, halogen, -CN, -NR7R14; R12 represents hydrogen or R13; R13 represents C1-5alkyl, hydroxyC1-4alkyl, cyanoC1-4alkyl, Cy2-C0alkyl or R14R7N-C1-4alkyl; where Cy2 is optionally substituted with one or several constituents R11; R14 represents hydrogen or C1-4alkyl; R16 represents C1-4alkyl, halogenC1-4alkyl, C1-4alkoxyC1-4alkyl, hydroxyC1-4alkyl or cyanoC1-4alkyl; Cy1 represents monocyclic carbocyclic unsaturated or saturated ring, selected from C3-C6cycloalkyl, phenyl, or saturated monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or partially unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available C atom, and where one or several ring C or S atoms are optionally oxidised with formation of CO or SO2; and Cy2 represents monocyclic carbocyclic unsaturated ring, selected from C3-C6cycloalkyl, or aromatic monocyclic 4-6-membered heterocyclic ring, containing from 1 to 2 heteroatoms, selected from N and S, or unsaturated 10-membered bicyclic heterocyclic ring, containing oxygen atom as heteroatom, which can be substituted with group R11, where said ring is bound with the remaining part of molecule via any available atom C or N.

EFFECT: obtaining novel heteroaryl derivatives.

27 cl, 41 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to quinolines substituted by phosphorus-containing group of formula and applicable in medicine, wherein Z represents V1 and V2 are independently specified in hydrogen or halogen; one of R and R` represent phosphorus-containing substitute Q; the other one is specified in hydrogen or methoxyl; wherein the phosphorus-containing substitute Q represents A represents O; L represents C1-6alkyl; J represents NH or C3-6heterocycloalkyl and J is optionally substituted by G3; X is absent or represents -C(=O)-; X is absent or represents C1-6alkyl; each of R1 and R2 are independently specified in C1-6alkyl or C1-6alkoxy; G3 represents C1-6alkyl, R3S(=O)m-, R5C(=O)- or R3R4NC(=O)-; R3, R4 and R5 are independently specified in 3 or C1-6alkyl; m is equal to 0-2.

EFFECT: there are presented new protein kinase inhibitors effective for treating the diseases associated with abnormal protein kinase activity.

20 cl, 42 ex, 8 tbl, 3 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a novel crystalline form of N-[-2[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azatidine-sulphonamide, which has an X-ray powder diffractogram, measured with the application of a wavelength of X-rays of 1.5418 E and containing, at least, one crystalline peak with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1; or containing, at least, 2 crystalline peaks with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1; or containing, at least, 3 crystalline peaks with a value 2-theta (in degrees) 21.0, 28.8 and/or 29.1. The said crystalline form can contain additional crystalline peaks with a value 2-theta (in degrees), selected from 12.9 and 18.0, obtained under the said conditions.

EFFECT: crystalline form has the X-ray powder diffractogram, measured with the application of a wavelength of X-rays of 1,5418 E, with the crystalline peaks with a value 2-theta (in degrees) 12,9, 13,1, 18,0, 21,0, 22,5, 25,1, 25,3, 28,8, 29,1 and 30,4, and has melting point (beginning) 152,7°C.

6 cl, 3 dwg, 2 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents using sulphated hyaluronic acid for preparing a therapeutic agent for local administration for treating inflammatory/irritating skin diseases specified in dermatitis, atopic dermatitis, photocontact dermatitis, rash, vitiligo, eczema, psoriasis, all skin irritations related to activation of anti-inflammatory cytokines, such as IL-1, IL-2, IL-7, IL-8, IL-9 and TNF, wherein hyaluronic acid has a molecular weight falling within the ranges of 10000 D to 50000 D, 150000 D to 250000 D and 500000 D to 750000 D, and a sulphatation degree equal to 1.

EFFECT: invention provides stimulating the immune system protein synthesis for eliciting the immune response.

8 cl, 33 ex, 15 dwg, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely urology, and can be used for treating advanced prostate cancer in male individuals. That is ensured by administering a therapeutically effective amount of a compound of formula IV or its isomer, a pharmaceutically acceptable salt, a pharmaceutical product, a polymorph, a hydrate or any combination thereof.

EFFECT: method provides treating effectively, inhibiting, reducing an incidence, relieving a severity or inhibiting advanced prostate cancer, as well as conducting the palliative treatment of advanced prostate cancer.

12 cl, 21 ex, 20 tbl, 23 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents a method of treating psoriasis or a related symptoms, in an individual, involving the local administration of a local composition containing a therapeutic effective amount of an α2 adrenergic receptor agonist and a pharmaceutically acceptable carrier on an individual's skin area, wherein the skin area is subject to psoriasis or the related symptom, or prone thereto, and wherein the α2 adrenergic receptor agonist is brimonidine.

EFFECT: invention provides developing the effective and safe method for treating or preventing psoriasis with no side effects or small side effects.

10 cl, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a local pharmaceutical composition for treating rosacea containing at least 0.02% berberine or a biologically equivalent berberine analogue, such as palmatine, and an ingredient specified in a group consisting of water, methanol, ethanol and dimethylsulphoxide, wherein berberine or the biologically equivalent berberine analogue represents the major pharmaceutically active ingredient.

EFFECT: invention provides extending the range of products for treating rosacea.

4 cl, 6 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and describes a non-aqueous ointment containing a compound of vitamin D, corticosteroid and ester of N,N-di(C1-C8)alkylamino-substituted (C4-C18)alkyl(C2-C18)carboxylic acid in Vaseline, optionally containing mineral oil and tocopherol.

EFFECT: ointment is characterised by storage stability and high skin penetration of the corticosteroid.

23 cl, 4 dwg, 5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound selected from a group consisting of compounds presented by formula:

In the above formula, R1 represents S-Alk-R, wherein Alk represents methylene, C2-C6 polymethylene bond or C3-C6 alkenylene bond, R represents -N=C(NR3R4)(NR5R6) or -NR7[(NR3R4)C=NR5], or -N=C(R8)(NR9R10), wherein R3-R10 represents H, Alk, Ar or (CH2)nAr, wherein Ar represents an aryl group, and n represents an integer from 1 to 13, or R3 and R4, or R4 and R5, or R5 and R7, or R3 and R7, or R9 and R10, or R8 and R9 together can represent -(CH2)x-, wherein x represents an integer from 2 to 5, and R2 is specified in a group consisting of hydroxyl, alkyl having from 1 to 7 carbon atoms, and substituted by alkyl hydroxyl having from 1 to 7 carbon atoms.

EFFECT: preparing new cyclosporine derivatives.

5 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology and medicine. What is presented is a method for differentiating pluripotent stem cell population recovered from recognised pluripotent stem cell lines into a cell population expressing markers specific for a pancreatic entoderm line co-expressing PDX1, NKX6.1, but not expressing CDX2 and NGN3.

EFFECT: method can be used for medical and biotechnological applications.

9 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: method involves administering insulin-producing cells in a dose of 500 thousand cells in a solution of isotropic gel 0.5 ml, 15% ascorbic acid 10 mcl and 0.1% hydrogen peroxide 10 mcl. The preparation is administered subcutaneously into theanterior abdominal wall in a projection of the pancreas.

EFFECT: method reduces the number of complications related to developing tissue incompatibility.

3 ex

FIELD: medicine.

SUBSTANCE: what is presented is a method for producing insulin-producing cells prepared of multipotent stem cells and able to secrete insulin with the use of a layer of nutrient cells.

EFFECT: use in pharmacological industry for producing insulin.

71 cl, 23 dwg, 17 ex

FIELD: medicine.

SUBSTANCE: newborn rabbits' pancreases are placed in a salt solution with an antibiotic at temperature 4-10°C and grounded microfragments. Further they are incubated in a free medium from serum at first incubation temperature 36.6 to 37°C, during a first incubation period with periodic replacement of a serum-free medium and removal of spontaneously collapsed undesired cells until at least 80% of the remained cells represent beta cells. It is followed by incubation in the serum-free medium periodically replaced at second incubation temperature 22 to 29°C, during a second incubation period until at least 78-90 % of the remained cells represent beta cells.

EFFECT: invention allows producing beta cells applicable for transplantation to patients with diabetes for stimulating natural insulin development.

4 cl, 40 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: group of inventions is referred to the area of medicine and can be used for treatment of acute destructive pancreatitis. Dual-lumen PVC drain tube corresponding to the length of a standard gastro-duodenal probe. The drain tube ends up at the level of the Treitz's ligament. It additionally contains a hole in a small passage made at the level of the duodenal bulb area inlet. Drugs that contain pancreatic enzymes are administered in the duodenal bulb area by this drain tube.

EFFECT: reduction of dependence on sandostatin-based drugs, improved treatment effectiveness.

2 cl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns Seakem Gold agarose coated granules containing secretory cells.

EFFECT: invention provides the smallest tissues inflammation in recipients.

40 cl, 8 ex, 1 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to pharmacology and medicine. Fin order to obtain medicine, which has tissue-specific activity, animal organs are subjected to freezing not later than after 2 hours after raw material collection at temperature not lower than 40°C, kept at temperature minus 20-22°C during not less than two months. To milled frozen raw material 5% solution of acetic acid is added, bringing suspension temperature to 60-70°C and extraction of peptides into solution is carried out with constant mixing during not less than 2 hours. Supernatant fluid is siphoned and filtered through tissue, after which purified extract is directed to tangential micro-filtering. Obtained filtrate is directed to solid-phase extraction. Chromatography is carried out and on output from columns fractions of solutions are collected. Fractions, which contain peptide components, are united and directed to vacuum-evaporating plant, after which obtained target product is lyophilised.

EFFECT: method application makes it possible to obtain peptide complex with molecular weight of peptide components included in it from 75 to 5200 Da, which demonstrates pronounced tissue-specific activity.

8 cl, 14 tbl, 14 ex

FIELD: medicine.

SUBSTANCE: application describes a method for preparing and administering pancreatine micropellet nuclei and such pancreatine micropellet nuclei prepared by said method which do not contain synthetic oils. Also, the application describes the entero-soluble coated pancreatine micropellets.

EFFECT: invention provides the improved method for preparing entero-soluble coated pancreatine micropellets which can be delivered to an optimum area of digestive system wherein a digestive enzyme action is required, particularly to upper intestines, for pancreatine release.

17 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to endocrinology, and deals with treatment of diabetes mellitus. For this purpose into abdomen hypodermic cellular tissue of recipient introduced is injection composition, including bio-degradable gel-containing matrix and cell suspension of primary culture of patient's pancreatic islet tissue.

EFFECT: method ensures normalisation of glucose level in blood for a long time period due to recovery of function of patient's pancreatic islet tissue.

5 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery and endocrinology, and can be used in the patients requiring a conservative treatment of acute pancreatitis. That is ensured by a standard medical therapy by the introduction of infusion preparations, anaesthetics, spasmolytics, vasoconstrictors, antibiotics, novocaine, cytostatics, omeprazole, sandostatin. For the period of treatment, hunger with voluminous drinking is prescribed. Pit of the stomach is cooled. In addition, procaine blocks in the round ligament of liver are applied that implements the introduction of at least 200 mg of Immunomax and 10 ml of 5-fluorouracil. During 2 days, at least 1.0 g of metronidazole, 0.1 g of furaginum, at least 15.0 g of Enterosgel are intaken. During the whole therapeutic course, at least 1 ml of Sporobacterine suspension together with cooled water is taken once a day. Starting from the sixth day and during the whole therapeutic course of hospital treatment, 1 tablet of Mezym forte 2 times a day is prescribed. For at least two weeks after discharge from the hospital, treatment in a locally available health resort is continued.

EFFECT: method allows reducing considerably the probability of acute pancreatitis transition into a destructive form due to the effect of specified therapy by various pathogenesis links of specified disease.

2 ex

FIELD: medicine.

SUBSTANCE: antianginal therapy is accompanied by a primary discrete plasmapheresis in a refrigerate centrifuge PC-6 having a rotating speed of 2,000 rpm for 15 minutes at a temperature of 22°C in number of 5 sessions every second day. One session involves removing the whole blood in an amount of: 2 flexible PVC packages x 450 ml if the patient's body weight index is from 18 to 29.9 kg/m2, 3 flexible PVC packages x 450 ml if the patient's body weight index is over 30 kg/m2. The total volume of the removed plasma makes 600-900 ml. The circulating blood volume is replaced with 0.9% NaCl in an amount of half as much as the removed plasma volume. Once the plasmapheresis course is completed, the blood is exposed to ultraviolet light generated by OVK-3 apparatus for at wave length more than 400 nm in number of 5 procedures every second day.

EFFECT: effective treatment of the given category of the patients by improving the haemorheology, normalising the lipid spectrum without increasing liver enzymes with preserving the hepatic function, decreasing the dyslipidemia level and functional class of angina in the patients with limited use of statins with underlying cholestasis.

2 tbl, 5 ex

Up!